Creative Medical (CELZ) Technology announced that the World Health Organization has approved “olastrocel” as the International Non-Proprietary Name for the active cellular substance in CELZ-201, the Company’s lead allogeneic cell therapy also known as AlloStem.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ:
- Creative Medical files to sell 2.79M shares of common stock for holders
- Creative Medical Technology Approves Executive Bonuses
- Creative Medical Technology’s New Warrant Agreements Announced
- Creative Medical launches Biodefense Inc. Veterans Initiative
- Creative Medical announces agreements for warrant exercise for $4.2M proceeds